BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOL has been the subject of a number of other reports. Ascendiant Capital Markets reduced their price target on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Benchmark reissued a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research report on Wednesday, October 2nd.

BIOLASE Price Performance

Shares of BIOL opened at $0.01 on Wednesday. BIOLASE has a 1-year low of $0.02 and a 1-year high of $1.94. The stock has a market cap of $167,035.00, a PE ratio of 0.00 and a beta of 0.67. The firm has a fifty day moving average price of $0.02 and a 200 day moving average price of $0.07.

Institutional Investors Weigh In On BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC grew its holdings in BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the period. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is currently owned by institutional investors and hedge funds.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.